Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUI8F3)

Drug Name

Friulimicin Drug Info

Synonyms

Friulimicin B; Friulimicin (antibacterial), Combinature; Friulimicin (antibiotic), Combinature; Friulimicin (iv, bacterial infection), Combinature; Friulimicin (iv, bacterial infection), Merlion; Friulimicin (topical, bacterial infection), Merlion

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 56842195
CAS Number: 239802-15-4
TTD Drug ID: DMUI8F3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bacterial Cell membrane (Bact CM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[3]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[4]
Delamanid	DMXE76K	Multi-drug resistant tuberculosis	MG52.00	Approved	[5]
Diphtheria-tetanus vaccine	DM0FSIM	Clostridium infection	1A04	Approved	[6]
D2A21	DMYJ2QB	Burn and burn infection	ND90-NE2Z	Phase 3	[7]
DPK-060	DM059CZ	Atopic dermatitis	EA80	Phase 2	[8]
Brilacidin	DMXI9BP	Acute bacterial skin infection	1C41	Phase 2	[9]
LTX-109	DMXEQ0R	Bacterial infection	1A00-1C4Z	Phase 2	[10]
IDR-1018	DM1RNT7	Bacterial infection	1A00-1C4Z	Phase 1	[11]
Lotilibcin	DMDLTCU	Bacterial infection	1A00-1C4Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Cell membrane (Bact CM)	TTXT4D5	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00492271) First Time in Man Trial for Friulimicin B. U.S. National Institutes of Health.
2	Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5	Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
6	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
7	In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
8	The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29.
9	Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
10	A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
11	Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
12	Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.